Botox — HCPCS J0585 · Therapeutic OnabotulinumtoxinA

About therapeutic Botox FDA label verified Jun 2026

Botox (onabotulinumtoxinA) is a purified botulinum toxin type A that works by chemodenervation: injected into a target muscle or gland, it cleaves the SNAP-25 protein and blocks acetylcholine release at the nerve terminal, producing a localized, temporary reduction in muscle contraction or glandular secretion. The effect develops over days, peaks in 1–2 weeks, and wears off over roughly 3 months — which is why nearly every therapeutic protocol re-treats on a 12-week cycle. It is a clinic-administered, buy-and-bill drug: the practice purchases the vials, injects in office, and bills the drug (J0585) plus an administration code to the medical benefit.

Originally developed by Allergan and now marketed by AbbVie, Botox carries one of the broadest therapeutic labels in the specialty-injectable space: chronic migraine, cervical dystonia, upper- and lower-limb spasticity, overactive bladder and neurogenic detrusor overactivity, blepharospasm, strabismus, and severe axillary hyperhidrosis. It is heavily used across neurology (migraine, dystonia, spasticity), urology (overactive bladder), physical-medicine & rehab (spasticity), and ENT/ophthalmology (blepharospasm/strabismus). The same molecule is also sold as Botox Cosmetic for glabellar and canthal lines — an important distinction for billers, because the cosmetic use is a self-pay service that is never submitted to a health plan.

From a billing standpoint, three features make Botox claims distinctive and error-prone. First, the administration code is not fixed — it is a chemodenervation CPT chosen by the body region and indication, billed in addition to J0585. Second, Botox ships in 100-unit and 200-unit single-dose vials, and because therapeutic doses rarely match a whole vial, leftover units are almost always discard-reported with JW/JZ. Third, the drug is prior-authorization heavy, with indication-specific clinical criteria, per-session unit caps, and a minimum 12-week interval that payers actively police.

A point of frequent confusion: Botox units are product-specific. They are not equivalent to Dysport, Xeomin, Myobloc, or Daxxify units, and each of those products has its own HCPCS J-code. A “155-unit” chronic-migraine dose is a Botox figure only. Coding a claim means matching the exact product administered to its own J-code and reporting the dose in that product’s own units — never converting between toxins. The botulinum-toxin product map below lays out the J-codes side by side.

Botulinum-toxin product map — each toxin has its own J-code and its own units CMS HCPCS aligned Jun 2026

There are five botulinum-toxin products on the US market. Their potency units are NOT interchangeable, and each maps to a different HCPCS code. Coding the wrong product’s J-code — or converting units between products — is a top claim-accuracy error.

Botox is one of five distinct botulinum-toxin products. Four are type A (onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, daxibotulinumtoxinA) and one is type B (rimabotulinumtoxinB). Critically, the “unit” printed on each label is a product-specific potency measure defined by that manufacturer’s own assay — there is no FDA-approved fixed conversion factor between products. Bill the J-code that matches the exact product administered, and report the dose in that product’s units.

Dose & units by indication FDA label verified Jun 2026

Botox dose is indication-specific, billed as J0585 × the number of units administered. The unit count and the matching chemodenervation admin CPT both flow from the indication.

Typical therapeutic dosing (Botox units)

Unit math — J0585 at 1 unit

J0585 is billed at 1 unit = 1 Botox unit, so the administered unit count is the billed unit count. Because Botox comes in 100- and 200-unit single-dose vials, choose the vial size that minimizes discard, then report the leftover with JW.

NDC reference Therapeutic NDCs verified vs FDA NDC Directory, Jun 2026

Single manufacturer (AbbVie/Allergan). Therapeutic Botox = two vial sizes (100 & 200 unit); pick the size that minimizes discard for the dose.

Administration codes (chemodenervation) CPT verified Jun 2026

There is no single “Botox CPT.” The administration code is a chemodenervation CPT chosen by body region and indication, billed in addition to the J0585 drug units. Guidance codes may be separately reportable.

Modifiers CMS verified Jun 2026

JW / JZ — single-dose vial waste reporting

Per CMS’s July 2023 single-dose-container policy (CR 12056), exactly one of JZ (no discard) or JW (discard) is required on J0585 claims. Botox is supplied only in single-dose 100/200-unit vials, so the modifier always applies. Because therapeutic doses rarely match a whole vial, JW is the common case:

Modifier 25 — same-day E/M

Append modifier 25 to the office E/M (99202–99215) when a significant, separately identifiable evaluation and management service is performed on the same day as the chemodenervation procedure. A routine pre-injection check is bundled into the procedure; a distinct problem-focused visit (e.g., reassessing migraine frequency and adjusting the plan) supports a separate 25-modified E/M.

Modifier 59 / X{EPSU} — distinct procedural service

Use a distinct-service modifier only when two separate, non-overlapping chemodenervation procedures are performed and an NCCI edit would otherwise bundle them (e.g., distinct anatomic regions). Most Botox sessions are a single chemodenervation code and need no 59. Do not use 59 to unbundle the guidance add-on from its base procedure.

340B modifiers (JG, TB) & KX

For 340B-acquired Botox at eligible covered entities, follow your MAC’s current 340B modifier policy (JG or TB as directed). Some payers also require KX to attest that indication-specific coverage criteria (e.g., the chronic-migraine clinical thresholds) are met — check the policy before submitting.

ICD-10-CM by indication FY2026 · verified Jun 2026

For Botox, the diagnosis is the coverage backbone — it is what makes the claim therapeutic (covered) rather than cosmetic (self-pay), and it must match the payer’s indication-specific policy. Code to the highest documented specificity.

Site of care & place of service Verified Jun 2026

Therapeutic Botox is overwhelmingly an in-office, buy-and-bill drug: the practice purchases the vials, injects in the clinic, and bills J0585 plus the chemodenervation CPT on a CMS-1500 (837P). Place of service drives both how the drug is acquired and how the admin code prices — office (POS 11) pays the practice for the drug and the procedure; hospital outpatient (POS 22) pays the facility, with the drug acquired under the facility (often 340B).

Claim form field mapping CMS verified Jun 2026

Office Botox is a CMS-1500 (837P) claim. HOPD/facility Botox is UB-04 (837I). The fields below map the office buy-and-bill claim; the facility claim mirrors them on the institutional form.

Payer policy snapshot Reviewed Jun 2026 · verify current policy

Therapeutic Botox is covered for FDA-approved indications, almost always with prior authorization. The PA criteria, per-session unit cap, and 12-week interval are the levers payers use — confirm the specific policy before the date of service.

The 12-week interval and unit cap are the recurring levers

Across payers the two most-enforced conditions are the minimum 12-week (84-day) interval between treatments and the per-session unit cap (commonly 155–195 units for chronic migraine, higher for spasticity). Re-treating even a few days early, or exceeding the approved unit count, produces a clean denial regardless of medical necessity. Track each PA’s approved unit limit, approved number of sessions, and next-eligible date alongside the claim, and document treatment response to support re-authorization. Policy specifics change — verify the current document for each payer.

Medical vs pharmacy benefit (white-bag check)

Therapeutic Botox is usually a medical-benefit buy-and-bill drug (the practice purchases and bills J0585). But a growing number of commercial plans and some Medicaid programs carve botulinum toxin to the pharmacy / specialty-pharmacy benefit and require white-bagging — the drug ships from a contracted specialty pharmacy to the office for a scheduled patient, and the practice bills only the administration (the chemodenervation CPT), not J0585. Confirm the benefit and source-of-supply during the prior-auth/benefit check: billing J0585 buy-and-bill when the plan mandates white-bag (or vice versa) is a clean denial. When white-bagged, there is no J0585 drug line or JW/JZ for the practice — the specialty pharmacy owns the drug claim.

Medicare reimbursement — J0585 reimbursement (2026) CMS ASP verified Q2 2026

J0585 is an ASP-priced Part B drug. Medicare pays the office ASP+6% allowed amount (subject to ~2% sequestration), and the patient owes ~20% coinsurance of that allowed amount for the administered units.

Coverage

There is no NCD specific to botulinum toxin; coverage runs through MAC chemodenervation LCDs/LCAs and the standard Part B drug framework. MACs cover J0585 for the FDA-approved therapeutic indications with the covered diagnosis, documented units/sites, and the 12-week interval. Cosmetic use is statutorily non-covered.

Code history

• J0585 — permanent HCPCS, “Injection, onabotulinumtoxinA, 1 unit.” The therapeutic/medical-benefit code for Botox. Distinct from the other botulinum toxins’ codes (J0586 Dysport, J0587 Myobloc, J0588 Xeomin, J0589 Daxxify).
• Cosmetic use — not reported to insurers with J0585; billed as a self-pay cosmetic service.

Patient assistance Verified Jun 2026

Because therapeutic Botox is a recurring (every-12-week) in-office drug, the manufacturer copay-card + foundation-bridge structure applies in the usual way. The dividing line is the patient’s insurance: commercially insured patients can use the AbbVie copay program; government-insured patients (Medicare, Medicaid, TRICARE) cannot, and route to foundations or the uninsured-patient program instead.

• BOTOX Savings Program (AbbVie) — commercial-insurance copay assistance. Eligible patients can pay as little as $0 out-of-pocket for Botox and the injection procedure, up to a program maximum of $4,000 per calendar year (commonly up to ~$1,400 for the first treatment and ~$1,000 each subsequent, ~5 treatments per 12 months). Enroll at botoxsavingsprogram.com or 1-800-44-BOTOX (800-442-6869). Not for patients with government insurance (Medicare/Medicaid/TRICARE). Verify current terms at enrollment.
• Allergan/AbbVie patient assistance (uninsured) — income-based free-drug program for qualifying uninsured patients; benefits-investigation and PA support for the practice.
• Independent foundations (for government-insured) — disease-specific copay funds (e.g., chronic-migraine funds at foundations such as HealthWell) may help Medicare patients when open; fund availability cycles, so check current status before relying on it.
• 340B — for eligible covered entities purchasing Botox under 340B, the discount accrues to the entity and is reported per the MAC’s 340B modifier policy; it does not directly change the patient’s coinsurance.

Common denials & how to fix them Reviewed Jun 2026

Frequently asked questions

What is the HCPCS J-code for therapeutic Botox?

Therapeutic Botox (onabotulinumtoxinA) is billed under J0585, “Injection, onabotulinumtoxinA, 1 unit.” One billed unit = 1 Botox unit, so a 155-unit chronic-migraine session is J0585 × 155. J0585 is the medical-benefit code for FDA-approved therapeutic indications. Cosmetic Botox (Botox Cosmetic for glabellar lines, crow’s feet, forehead lines) is not billed to medical insurance — it is a patient self-pay service and is not reported with J0585 to a health plan.

Are Botox units interchangeable with Dysport, Xeomin, or Myobloc?

No. Botulinum-toxin units are product-specific and not interchangeable. Botox (onabotulinumtoxinA, J0585), Dysport (abobotulinumtoxinA, J0586), Xeomin (incobotulinumtoxinA, J0588), Myobloc (rimabotulinumtoxinB, J0587), and Daxxify (daxibotulinumtoxinA, J0589) each have their own potency unit and their own J-code. A “155-unit” migraine dose is a Botox figure only. Bill the J-code that matches the exact product administered, in that product’s own units — cross-walking units between products is a clinical-safety and claim-accuracy error. See the product map.

How do I bill Botox vial waste with JW and JZ?

Botox is supplied in 100/200-unit single-dose vials and is on the CMS single-dose-container list, so each claim needs JZ (no discard) or JW (discard) per CR 12056. Example: a 155-unit dose from one 200-unit vial leaves 45 units discarded — bill J0585 × 155 administered plus a separate J0585 line with modifier JW × 45. If two 100-unit vials are opened for the same 155 units, 200 are opened and 45 are still JW. When the full vial is used with nothing discarded, use JZ. Reconcile billed units to vials opened on the drug-prep log.

Which CPT code do I use to administer Botox?

Botox administration uses a chemodenervation CPT chosen by region/indication, billed in addition to J0585: 64615 chronic migraine, 64616 cervical dystonia, 64612 blepharospasm/face, 64617 larynx, 64642–64645 limb spasticity, 64646/64647 trunk, 67345 strabismus, 52287 overactive bladder (intradetrusor), and 64650/64653 hyperhidrosis. EMG/e-stim guidance (95873/95874) and ultrasound guidance (76942) may be separately reportable. There is no single “Botox CPT.”

How many Botox units are used for chronic migraine and how often?

The FDA-approved chronic-migraine protocol (PREEMPT) is 155 units across 31 fixed sites in 7 head/neck muscle groups, repeated every 12 weeks (~84 days); some payers allow a follow-the-pain protocol up to 195 units. Most plans require chronic migraine defined as 15+ headache days/month with documented failure of 2+ oral prophylactic classes before approving Botox. Bill J0585 × 155 (or the documented count) plus admin CPT 64615, and report JW waste from the vial.

Is therapeutic Botox covered by insurance, and how is it different from cosmetic Botox?

Therapeutic Botox is covered under the medical benefit (buy-and-bill: J0585 + a chemodenervation CPT) for FDA-approved indications such as chronic migraine, cervical dystonia, spasticity, overactive bladder, blepharospasm, strabismus, and severe axillary hyperhidrosis — generally with prior authorization. Cosmetic Botox for wrinkles is not a covered medical service; it is patient self-pay and is not submitted to the plan. The same molecule can be used either way — what determines coverage is the documented diagnosis and indication, so the ICD-10 and medical-necessity documentation are the dividing line.

Does Botox require prior authorization?

Yes — almost all therapeutic Botox indications require PA, and it is one of the most PA-intensive buy-and-bill drugs. Payers require the indication-specific clinical criteria (for chronic migraine: 15+ headache days/month and failure of 2+ oral prophylactics; for spasticity/dystonia: the qualifying neurologic diagnosis), a per-session unit cap (commonly 155–195 for migraine, up to 400 for spasticity), and a minimum 12-week interval. Missing/expired PA, exceeding the unit cap, or re-treating early are the top denial drivers.

Is Botox a medical benefit or a pharmacy benefit?

Therapeutic Botox is usually a medical-benefit, buy-and-bill drug — the practice purchases the vials and bills J0585 plus a chemodenervation CPT. However, some commercial plans and Medicaid programs cover botulinum toxin only under the pharmacy / specialty-pharmacy benefit and require white-bagging: a specialty pharmacy ships the drug to the office and the practice bills only the administration code (not J0585, and no JW/JZ). Always confirm the benefit type and source of supply during the prior-auth/benefit check — billing buy-and-bill when the plan mandates white-bag (or vice versa) is a clean denial. (Cosmetic Botox is neither — it’s patient self-pay.)

What is the patient’s cost for Botox, and is there copay assistance?

For Medicare Part B, the patient typically owes ~20% coinsurance of the J0585 allowed amount (ASP+6%) for the units given, plus their share of the admin CPT, unless they have secondary coverage — run a CareCost Estimate for the exact figure. For commercially insured patients, the BOTOX Savings Program can reduce eligible out-of-pocket to as little as $0, up to a program maximum (generally $4,000/year, ~5 treatments per 12 months), limited to a set number of treatments per 12 months. Manufacturer copay programs cannot be used by patients with government insurance.

Can I bill EMG or ultrasound guidance with a Botox injection?

Often yes, when guidance is performed and documented. Needle EMG/e-stim guidance is reported with 95874/95873 and ultrasound guidance with 76942, each as an add-on to the chemodenervation CPT. Guidance is most commonly supported for limb spasticity and cervical dystonia (deep-muscle targeting) and is generally not separately reported for the fixed-site PREEMPT migraine protocol. Document the modality in the procedure note — unsupported guidance add-ons are a common post-pay takeback.

Source documents

1. DailyMed — Botox (onabotulinumtoxinA) prescribing information
   Current FDA label; therapeutic indications, dosing by indication, reconstitution, units (product-specific)
2. CMS HCPCS Level II — J0585
   “Injection, onabotulinumtoxinA, 1 unit”; distinct from J0586/J0587/J0588/J0589
3. CMS — Medicare Part B Drug ASP Pricing File
   Quarterly ASP+6% pricing; J0585 = $6.512/unit (Q2 2026), live-bound on this page
4. CMS — JW/JZ modifier policy (CR 12056, eff. July 2023)
   Single-dose-container discard reporting; applies to Botox 100/200-unit single-dose vials
5. FDA National Drug Code Directory — Botox NDCs
   Verify the 11-digit NDC for the exact 100/200-unit vial used
6. AMA CPT — chemodenervation codes (64612–64653, 67345, 52287) & guidance (95873/95874, 76942)
   Indication-specific administration codes for botulinum-toxin injection
7. American Academy of Neurology — botulinum toxin practice guidelines (migraine, spasticity, dystonia)
   Evidence-based use; the PREEMPT 155-unit chronic-migraine protocol
8. CMS — ICD-10-CM (FY2026)
   G43.7xx chronic migraine; G24.x dystonia; G80.x/I69.x spasticity; N32.81/N31.x bladder; L74.510 hyperhidrosis
9. UnitedHealthcare — Medical Benefit Drug Policy: Botulinum Toxins
   PA criteria, indication-specific unit caps, 12-week interval, step-therapy for migraine
10. Aetna Clinical Policy Bulletins — Botulinum Toxins
    Covered therapeutic indications; cosmetic not covered; PA requirements
11. Cigna — Coverage Policy: Botulinum Toxins
    Indication criteria, unit limits, 12-week interval, re-authorization on response
12. AbbVie — BOTOX Savings Program
    Commercial-insurance copay assistance ($0 eligible; annual maximums); 800-442-6869. Not for government-insured patients.

About this page

We maintain this page as a living reference for billers, coders, and revenue-cycle staff working with therapeutic Botox claims in neurology, urology, PM&R, and related specialties. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes. The J0585 ASP figure is live-bound to the CareCost CMS ASP layer, so the per-unit price reflects the current quarter automatically.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• Jun 25, 2026 — Red/Blue/Green review pass: verified codes/CPT/ICD-10/JW math against FDA/CMS/AMA primary sources; corrected the vial list to therapeutic 100/200-unit only (removed the cosmetic 50-unit NDC); tightened the BOTOX Savings Program terms; bound all per-unit ASP displays to the CMS file; added a medical-vs-pharmacy (white-bag) section + FAQ and HowTo schema for the JW math.
• Jun 25, 2026 — Initial publication. Therapeutic-Botox billing reference: J0585 per-unit with live ASP binding; botulinum-toxin product map (non-interchangeable units / separate J-codes); indication-specific chemodenervation admin CPTs; 100/200-unit single-dose vial JW/JZ discard math; prior-auth criteria (unit caps + 12-week interval); therapeutic-vs-cosmetic distinction; BOTOX Savings Program.

Methodology

Every claim on this page is sourced inline. Dosing, indications, and the units-are-product-specific rule are taken from the current FDA prescribing information; the ASP figure is read live from the CMS Part B ASP file; administration codes are from AMA CPT; and payer rules are read directly from each plan’s published botulinum-toxin medical policy. We do not paraphrase from billing-software vendor blogs, and we flag anything not yet SME-verified rather than assert it.